Abstract
Hodgkin Lymphoma (HL) represents one of the most common types of a non-AIDS-defining tumour that occurs in the HIV population, and its incidence is increasing in the post Highly Active Anti-retroviral Therapy (HAART) era. Despite the aggressiveness of that disease, the outcome of patients with HIV-HL has improved with better, combined antineoplastic and antiretroviral approaches. New and effective antiretroviral drugs, in conjunction with nucleoside analogs, improve the control of the underlying HIV infection when used during treatment of HL with chemotherapy. The inclusion of hematopoietic growth factors in the treatment of patients with HIV-HL may allow for the administration of higher dose-intensity chemotherapy and the prolonged use of antiretroviral drugs, with the aim of improving the survival. In addition, new functional imaging tools, like the Positron Emission Tomography (PET), may help to guide treatment and minimize long term toxicity.
Keywords: Hodgkin lymphoma, HIV, non-AIDS-defining tumour, chemotherapy
Current HIV Research
Title: Hodgkin Lymphoma in HIV Positive Patients
Volume: 8 Issue: 2
Author(s): Nicolas Mounier, Michele Spina and Jean P. Spano
Affiliation:
Keywords: Hodgkin lymphoma, HIV, non-AIDS-defining tumour, chemotherapy
Abstract: Hodgkin Lymphoma (HL) represents one of the most common types of a non-AIDS-defining tumour that occurs in the HIV population, and its incidence is increasing in the post Highly Active Anti-retroviral Therapy (HAART) era. Despite the aggressiveness of that disease, the outcome of patients with HIV-HL has improved with better, combined antineoplastic and antiretroviral approaches. New and effective antiretroviral drugs, in conjunction with nucleoside analogs, improve the control of the underlying HIV infection when used during treatment of HL with chemotherapy. The inclusion of hematopoietic growth factors in the treatment of patients with HIV-HL may allow for the administration of higher dose-intensity chemotherapy and the prolonged use of antiretroviral drugs, with the aim of improving the survival. In addition, new functional imaging tools, like the Positron Emission Tomography (PET), may help to guide treatment and minimize long term toxicity.
Export Options
About this article
Cite this article as:
Mounier Nicolas, Spina Michele and Spano P. Jean, Hodgkin Lymphoma in HIV Positive Patients, Current HIV Research 2010; 8 (2) . https://dx.doi.org/10.2174/157016210790442704
DOI https://dx.doi.org/10.2174/157016210790442704 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Current Pharmaceutical Biotechnology Glycolipid Stimulators for NKT Cells Bearing Invariant Vα19-Jα33 TCR α Chains
Mini-Reviews in Medicinal Chemistry Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry Novel Anti-Inflammatory and Neuroprotective Agents for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Protective Effect of Heat Shock Proteins in the Nervous System
Current Neurovascular Research Macrolide Hybrid Compounds: Drug Discovery Opportunities in Anti- Infective and Anti-inflammatory Area
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Reviews on Recent Clinical Trials Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs
Current Medicinal Chemistry Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Fc Engineering to Improve the Function of Therapeutic Antibodies
Current Pharmaceutical Biotechnology Phosphonomethoxyalkyl Analogs of Nucleotides
Current Pharmaceutical Design The ALK Gene, An Attractive Target for Inhibitor Development
Current Topics in Medicinal Chemistry Coordinated Expression of Pax-5 and FAK1 in Metastasis
Anti-Cancer Agents in Medicinal Chemistry Targetin g Human Tel omerase by Antisens e Oligonucleotides and Ribozymes
Current Medicinal Chemistry - Anti-Cancer Agents Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Biological Evaluation of Scutellaria Flavone Cyclaneaminol Mannich Base Derivatives as Novel CDK1 Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design Prevalence of Oral and Systemic Manifestations in Pediatric HIV Cohorts with and without Drug Therapy
Current HIV Research